Vireo Growth Total Liabilities 2023-2025 | VREOF

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Vireo Growth total liabilities from 2023 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Vireo Growth total liabilities from 2023 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$218.7B
Boston Scientific (BSX)	$152.6B
Stryker (SYK)	$150.8B
EssilorLuxottica (ESLOY)	$131.9B
Medtronic (MDT)	$117.5B
Lonza Group Ag (LZAGY)	$49.6B
Haleon (HLN)	$43.4B
ResMed (RMD)	$39.2B
GE HealthCare Technologies (GEHC)	$35B
Agilent Technologies (A)	$33B
Koninklijke Philips (PHG)	$24.1B
Terumo (TRUMY)	$23.6B
Insulet (PODD)	$20.1B
Zimmer Biomet Holdings (ZBH)	$19.1B
Baxter (BAX)	$14.1B
Smith & Nephew SNATS (SNN)	$13.5B
Sunny Optical Technology (SNPTF)	$10.4B
Demant (WILYY)	$8.6B
Bio-Rad Laboratories (BIO)	$6.7B
Lantheus Holdings (LNTH)	$5B
Perrigo (PRGO)	$3.8B
Prestige Consumer Healthcare (PBH)	$3.8B
Haemonetics (HAE)	$3.6B
Shandong Weigao Medical Polymer (SHWGF)	$3.5B
Envista Holdings (NVST)	$3.4B
ICU Medical (ICUI)	$3.1B
LeMaitre Vascular (LMAT)	$1.8B
QuidelOrtho (QDEL)	$1.7B
AtriCure (ATRC)	$1.5B
Acuren (TIC)	$1.4B